Navigation Links
NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
Date:3/19/2009

or forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of the European Commission's decision on the CHMP's recommendation for approval of the MAA for Qutenza in the European Union; NeurogesX' plans to seek and timing to obtain a commercial partner for Qutenza in Europe; the expected benefits of NeurogesX' product candidates and its plans with regard to seeking potential development partners for its early stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.           The Ruth Group
    Stephen Ghiglieri         Stephanie Carrington / Sara Ephraim (investors)
    Chief Financial Officer   (646) 536-7017 / 7002
    (650) 358-3310            scarrington@ther
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
2. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
3. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
4. NeurogesX Reports Third Quarter 2008 Results
5. NeurogesX to Report Third Quarter 2008 Financial Results
6. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
7. NeurogesX Responds to EMEAs Day 120 Questions
8. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
9. NeurogesX Reports Second Quarter 2008 Results
10. NeurogesX to Report Second Quarter 2008 Financial Results
11. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... -- An entire month is dedicated to one of the ... (CMT) – a debilitating neuromuscular disease affecting the arms, ... and foot and hand deformities. CMT affects 1 in ... a progressive disease, and over time patients lose the ... as leg braces, wheelchairs and scooters to get around. ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... preclinical studies characterizing the analgesic profiles of a ... opioid receptor agonist molecules. The preclinical research candidates ... chemistry platform. The analgesic properties of ... medical literature. 1,2 Kappa opioid receptors are ...
(Date:9/19/2014)... 2014 BioTech News Coverage: Progress ... results of studies and trials.  Companies in focus are: ... LLY ), Gilead Sciences Inc. (NASDAQ: ... ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... therapeutics for the treatment of cancer, announced that the ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7
... High transduction efficiency and predictable copy number , ... , Katherine Felts John C. Bauer Peter ... pFB-Neo can be used with any,Moloney Murine Leukemia Virus ... be used to infect a wide range of cell ...
... expression of heterologous proteins , Carsten-Peter Carstens ... ,Stratagene , Codon bias is a significant obstacle ... hosts. In GC-rich genomes, such as mammals,rare arginine ... (CCC) most frequently,affect bacterial gene expression. For such ...
... mixture, TaqPlus Precision PCR system, developed for,highfidelity PCR ... Frances Bai * Daniel McMullan,* Barbara McGowan * Holly ... the addition of the TaqPlus Precision PCR system,* to ... PCR system,consists of a novel mixture of Taq2000 and ...
Cached Biology Technology:High-Titer ,Retroviral Vectors for Gene Delivery 2High-Titer ,Retroviral Vectors for Gene Delivery 3High-Titer ,Retroviral Vectors for Gene Delivery 4High-Titer ,Retroviral Vectors for Gene Delivery 5High-Titer ,Retroviral Vectors for Gene Delivery 6High-Titer ,Retroviral Vectors for Gene Delivery 7High-Titer ,Retroviral Vectors for Gene Delivery 8New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 2New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 3New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 4High-Fidelity PCR with a Novel Polymerase Mixture 2High-Fidelity PCR with a Novel Polymerase Mixture 3High-Fidelity PCR with a Novel Polymerase Mixture 4High-Fidelity PCR with a Novel Polymerase Mixture 5High-Fidelity PCR with a Novel Polymerase Mixture 6High-Fidelity PCR with a Novel Polymerase Mixture 7High-Fidelity PCR with a Novel Polymerase Mixture 8High-Fidelity PCR with a Novel Polymerase Mixture 9High-Fidelity PCR with a Novel Polymerase Mixture 10High-Fidelity PCR with a Novel Polymerase Mixture 11
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
(Date:9/18/2014)... turned its newborn screening program into a model other states ... the first-ever Newborn Screening Quality Award from the March of ... M.P.H., Arizona,s Department of Health Services director, with the award ... policy of full transparency for the length of time it ... lab for analysis, and set a target of having 95 ...
(Date:9/18/2014)... Eight researchers from several disciplines will be celebrated tonight ... their roles in improving the health of premature infants ... supercomputing revolutions. The researchers, whose work was supported by ... and the former Atomic Energy Commission, will be honored ... Washington, DC. A bipartisan group of Members of Congress ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... (BRONX, NY) Researchers from the Albert Einstein ... developed an onsite method to quickly diagnose tuberculosis (TB) ... undetected with treatable TB strains. This study will ... online journal from the Public Library of Science. ...
... 19, 2009Recognition of the benefits of cooling strategies to ... has led to a wealth of cutting edge research, ... hypothermia issue of Journal of Neurotrauma , a ... www.liebertpub.com ). The issue will be available free online ...
... is 2065. Nearly two-thirds of Earth,s ozone is gone -- ... hole over Antarctica, first discovered in the 1980s, is a ... ultraviolet (UV) radiation falling on mid-latitude cities like Washington, D.C., ... DNA-mutating UV radiation is up 650 percent, with likely harmful ...
Cached Biology News:Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time 2Therapeutic hypothermia is promising strategy to minimize tissue damage 2New simulation shows consequences of a world without Earth's natural sunscreen 2New simulation shows consequences of a world without Earth's natural sunscreen 3New simulation shows consequences of a world without Earth's natural sunscreen 4
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Request Info...
... Storage Racks for Standard 3" Boxes. ... all makes and models of upright ... high quality stainless steel and can ... steel or plastic boxes. Custom ...
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: